Brief: Cns Pharmaceuticals Completes Drug Product Manufacturing Strategy For Berubicin
15/07/2020 14:13
CNS Pharmaceuticals Inc CNSP.O :
* CNS PHARMACEUTICALS COMPLETES DRUG PRODUCT MANUFACTURING
STRATEGY FOR BERUBICIN
* CNS PHARMACEUTICALS - DECIDED TO IMPLEMENT A DUAL-TRACK
DRUG
PRODUCT MANUFACTURING STRATEGY FOR BERUBICIN TO MITIGATE BOTH
COVID-19 RELATED RISKS
Source text for Eikon: ID:nPn8CD2sMa
Further company coverage: CNSP.O
Recent news on CNS Pharmaceuticals
See all newsCNS Pharmaceuticals Q2 net loss widens, cash rises after financing
CNS Pharmaceuticals Inc expected to post a loss of 24 cents a share - Earnings Preview
NASDAQ RESUMED AT 09:44 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:32 AM
Brief: Cns Pharmaceuticals Appoints Rami Levin As CEO Effective Jan 1, 2026